Adicet Bio, Inc. (ACET) Bundle
A Brief History of Adicet Bio, Inc. (ACET)
Company Overview
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf allogeneic gamma delta T cell therapies for cancer and other immune disorders.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $12.4 million | $64.3 million | $156.1 million |
Key Pipeline Developments
- ADI-001 - Advanced T cell therapy for solid tumors
- ADI-002 - Targeting hematological malignancies
- Ongoing clinical trials in multiple cancer indications
Stock Performance
| Stock Symbol | NASDAQ Listing | 2024 Stock Price Range | Market Capitalization |
|---|---|---|---|
| ACET | Listed in 2020 | $3.50 - $6.25 | $180 million |
Research Collaborations
- Partnership with MD Anderson Cancer Center
- Collaboration with Memorial Sloan Kettering Cancer Center
Institutional Investors
| Top Institutional Holders | Shares Owned | Percentage of Ownership |
|---|---|---|
| Perceptive Advisors | 2.4 million shares | 12.3% |
| Vanguard Group | 1.9 million shares | 9.7% |
A Who Owns Adicet Bio, Inc. (ACET)
Major Institutional Shareholders
| Shareholder | Number of Shares | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 1,347,813 | 9.78% |
| BlackRock Inc. | 1,103,761 | 8.01% |
| Orbimed Advisors LLC | 4,080,000 | 29.61% |
Top Insider Owners
- Chen Schor (President and CEO): 178,371 shares
- Aya Jakobovits (Founder): 142,857 shares
- Daniel Teper (Executive Chairman): 106,529 shares
Ownership Structure
Public Float: 13,773,000 shares
Total Outstanding Shares: 14,729,000 shares
Venture Capital Investors
| Investor | Investment Amount | Ownership Percentage |
|---|---|---|
| Fidelity Management | $12.3 million | 6.45% |
| Baker Bros. Advisors | $18.7 million | 11.22% |
Adicet Bio, Inc. (ACET) Mission Statement
Company Overview
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf allogeneic gamma delta T cell therapies for cancer and other immune-mediated diseases.
Financial Performance
| Fiscal Year | Total Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $12.4 million | ($84.3 million) | $141.2 million |
Research and Development Focus
- Developing ADI-011 for solid tumors
- Advancing ADI-007 for hematologic malignancies
- Exploring off-the-shelf gamma delta T cell therapies
Clinical Pipeline
| Program | Indication | Clinical Stage |
|---|---|---|
| ADI-011 | Solid Tumors | Phase 1/2 |
| ADI-007 | Hematologic Malignancies | Phase 1 |
Strategic Objectives
Key objectives include advancing clinical development, expanding therapeutic applications, and maintaining robust financial resources for continued research.
Corporate Metrics
- Nasdaq-listed company (ACET)
- Approximately 90 employees
- Headquartered in Boston, Massachusetts
How Adicet Bio, Inc. (ACET) Works
Company Overview
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for cancer and other immune-mediated diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.8 million |
| Net Loss | $59.4 million |
| Cash and Cash Equivalents | $152.4 million |
Research and Development Focus
- Developing off-the-shelf gamma delta T cell therapies
- Targeting solid tumors and hematologic malignancies
- Utilizing proprietary cell engineering platform
Clinical Pipeline
| Program | Indication | Clinical Stage |
|---|---|---|
| ADI-011 | Solid Tumors | Phase 1/2 |
| ADI-222 | B-cell Malignancies | Preclinical |
Key Technology
Allogeneic gamma delta T cell platform enables development of standardized, off-the-shelf cell therapies with potential for multiple cancer indications.
Operational Details
- Headquartered in Boston, Massachusetts
- Founded in 2015
- NASDAQ-listed company under ticker ACET
Stock Performance
| Metric | Value |
|---|---|
| Stock Price (as of January 2024) | $3.87 |
| Market Capitalization | $197 million |
How Adicet Bio, Inc. (ACET) Makes Money
Revenue Streams
Adicet Bio, Inc. generated total revenue of $11.4 million for the fiscal year 2023, primarily from research collaborations and grants.
| Revenue Source | Amount ($) |
|---|---|
| Research Collaboration Revenue | 7.2 million |
| Grant Revenue | 4.2 million |
Research and Development Funding
Adicet Bio secures funding through multiple channels:
- National Institutes of Health (NIH) grants
- Department of Defense research contracts
- Private investment partnerships
Product Development Pipeline
The company focuses on developing off-the-shelf gamma delta CAR-T cell therapies targeting various cancer types.
| Product Candidate | Development Stage | Potential Market |
|---|---|---|
| ADI-001 | Phase 1 Clinical Trial | Hematologic Cancers |
| ADI-002 | Preclinical Stage | Solid Tumors |
Financial Performance
As of Q4 2023, Adicet Bio reported:
- Cash and cash equivalents: $156.7 million
- Net loss: $49.3 million
- Research and development expenses: $37.2 million
Strategic Partnerships
Adicet Bio generates revenue through strategic collaborations with pharmaceutical companies.
| Partner | Collaboration Focus | Potential Milestone Payments |
|---|---|---|
| Regeneron Pharmaceuticals | CAR-T Cell Therapy Development | Up to $750 million |
Adicet Bio, Inc. (ACET) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.